Serum Calciprotein Monomers and Chronic Kidney Disease Progression

被引:4
|
作者
Tiong, Mark K. [1 ,2 ]
Holt, Stephen G. [1 ,2 ,3 ,4 ]
Ford, Martin L. [5 ,6 ]
Smith, Edward R. [1 ,2 ]
机构
[1] Royal Melbourne Hosp, Dept Nephrol, Parkville, Vic, Australia
[2] Univ Melbourne, Dept Med RMH, Parkville, Vic, Australia
[3] Abu Dhabi Hlth Serv Co, SEHA Kidney Care, Abu Dhabi, U Arab Emirates
[4] Khalifa Univ, Dept Med, Abu Dhabi, U Arab Emirates
[5] Kings Coll Hosp NHS Fdn Trust, Dept Renal Med, London, England
[6] Kings Coll London, Fac Life Sci & Med, London, England
关键词
Calciprotein monomers; Calciprotein particles; Chronic kidney disease; Mineral metabolism disorders; GROWTH-FACTOR; 23; FETUIN-A; PARATHYROID-HORMONE; PHOSPHATE; PARTICLES; MORTALITY; THERAPY; CALCIUM; DECLINE; RISKS;
D O I
10.1159/000526609
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Elevated levels of fibroblast growth factor-23 (FGF23) in chronic kidney disease (CKD) are associated with progression of CKD. FGF23 inhibits proximal tubular phosphate reabsorption, raising phosphate concentrations in the tubular fluid of functioning nephrons, predisposing to spontaneous precipitation of calcium phosphate crystals and resultant tubular injury. Calciprotein monomers (CPM) form spontaneously in biological fluids when clusters of calcium phosphate ions are bound by the liver-derived glycoprotein fetuin-A. Serum CPM are elevated in CKD and are postulated to trigger FGF23 secretion. CPM are also readily filtered at the glomerulus into the tubular fluid, suggesting that higher CPM levels could be associated with progression of CKD via FGF23-mediated increased phosphate load but also through direct effects in the proximal tubule. Methods: ACADEMIC was a prospective observational study of 200 stable outpatients with CKD stages 3 and 4. Participants were followed until commencement of dialysis or death. In this study, we examined a sub-cohort of 189 participants who had baseline serum available for measurement of CPM. Cox proportionate hazard regression models were used to examine the association between CPM and a composite kidney disease outcome (commencement of dialysis or reduction in estimated glomerular filtration rate [eGFR] >30%). Linear regression models were used to examine the association between CPM and annualized eGFR slope. Results: Relative to the lowest tertile, the highest tertile of CPM was associated with increased risk of the composite kidney disease outcome in univariate models and after sequential adjustment for conventional risk factors for progression of CKD (adjusted hazard ratio 4.22; 95% confidence interval [CI] 1.91, 9.33, p < 0.001). Natural log-transformed CPM was also inversely associated with eGFR slope in univariate and multivariate adjusted models (adjusted beta-coefficient -1.66, 95% CI: -3.10, -0.22, p = 0.024). In exploratory mediation analysis, the association between serum CPM and eGFR slope was partially mediated by iFGF23; however, the majority of the association was direct and independent of the iFGF23 pathway. Conclusion: Elevated levels of CPM are associated with the progression of CKD. This association was partially mediated via FGF23, consistent with recent evidence that FGF23 predisposes to spontaneous precipitation of calcium phosphate crystals leading to tubular injury. However, serum CPM also appeared to have a direct association with eGFR slope, raising the possibility that CPM may also be associated with progression of CKD through additional pathways.
引用
收藏
页码:806 / 815
页数:10
相关论文
共 50 条
  • [31] Mechanisms of progression of chronic kidney disease
    Fogo, Agnes B.
    PEDIATRIC NEPHROLOGY, 2007, 22 (12) : 2011 - 2022
  • [32] Mechanisms of progression of chronic kidney disease
    Agnes B. Fogo
    Pediatric Nephrology, 2007, 22 : 2011 - 2022
  • [33] Phosphate in Chronic Kidney Disease Progression
    Cozzolino, Mario
    Foque, Denis
    Ciceri, Paola
    Galassi, Andrea
    CURRENT PERSPECTIVES IN KIDNEY DISEASES, 2017, 190 : 71 - 82
  • [34] PROGRESSION AND PREVENTION OF CHRONIC KIDNEY DISEASE
    Ojo, Afolabi Michael
    Oluwasegun, Sulaimon Akeem
    NEPHROLOGY, 2005, 10 : A135 - A135
  • [35] Retarding progression of chronic kidney disease
    Saritas, Turgay
    Floege, Juergen
    INNERE MEDIZIN, 2023, 64 (03): : 240 - 246
  • [36] Targeting the progression of chronic kidney disease
    Marta Ruiz-Ortega
    Sandra Rayego-Mateos
    Santiago Lamas
    Alberto Ortiz
    Raul R. Rodrigues-Diez
    Nature Reviews Nephrology, 2020, 16 : 269 - 288
  • [37] Gender and the Progression of Chronic Kidney Disease
    Neugarten, Joel
    MAYO CLINIC PROCEEDINGS, 2020, 95 (12) : 2582 - 2584
  • [38] Atheroma Progression in Chronic Kidney Disease
    Rigatto, Claudio
    Levin, Adeera
    House, Andrew A.
    Barrett, Brendan
    Carlisle, Euan
    Fine, Adrian
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 4 (02): : 291 - 298
  • [39] Slowing the progression of chronic kidney disease
    Herrington, William G.
    Mason, Phil D.
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2009, 70 (11) : 634 - 638
  • [40] Acidosis and progression of chronic kidney disease
    Yaqoob, Muhammad M.
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2010, 19 (05): : 489 - 492